Bevacizumab plus chemo for first-line advanced colorectal cancer
Part of Cancer, Digestive system clinical trials.
This trial tests whether adding a drug called bevacizumab (which helps stop blood vessel growth to tumors) to a combination of two chemotherapy drugs (oxaliplatin and TAS-102) can help people with advanced colorectal cancer. It is for people who have not yet received treatment for their advanced cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You must have advanced colorectal cancer that has not been treated before with standard therapy.
- You should be in generally good health, with normal blood counts and heart, kidney, and liver function.
- You must have at least one tumor that can be measured on scans.
- You must be willing to use effective birth control if you are of childbearing age.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new targeted drug (SHR-A1811) combined with chemotherapy and bevacizumab versus the usual therapy for advanced colorectal cancer that hasn't been treated yet. It aims to see if the new combo works better as a first treatment.
This trial tests a new combination of drugs (liposomal irinotecan, 5-FU/LV, and bevacizumab) for people with advanced colorectal cancer that cannot be removed by surgery. The goal is to see if this treatment is safe and effective in shrinking tumors and improving outcomes.
This trial tests a new drug combination for people with colorectal cancer that has spread and cannot be removed by surgery. It compares the new drug plus standard chemotherapy against a placebo plus the same chemotherapy, to see if it helps shrink tumors and slow the disease.
This trial tests a combination of liposomal irinotecan, two chemotherapy drugs (leucovorin and 5-fluorouracil), and bevacizumab as a second-line treatment for people with colorectal cancer that has spread and cannot be removed by surgery.
This trial is for people with advanced colorectal cancer who are unable to receive standard combination chemotherapy. It tests a combination of two drugs, TAS-102 and bevacizumab, as the first treatment for their condition. The goal is to see if this combination can help slow the growth of the cancer and improve quality of life.
This trial tests adding a new drug combo (TAS-102 and bevacizumab) to standard second-line treatment for advanced colorectal cancer, followed by local treatments. It may help if your first treatment stopped working and you are otherwise in good health.
Hear when a new Advanced Colorectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.